MIDSHIPS: Multicentre Intervention Designed for Self-Harm using Interpersonal Problem-Solving: protocol for a randomised controlled feasibility study. by Collinson, M et al.
TRIALS
Collinson et al. Trials 2014, 15:163
http://www.trialsjournal.com/content/15/1/163STUDY PROTOCOL Open AccessMIDSHIPS: Multicentre Intervention Designed for
Self-Harm using Interpersonal Problem-Solving:
protocol for a randomised controlled feasibility
study
Michelle Collinson1*, David Owens2*, Paul Blenkiron3, Kayleigh Burton1, Liz Graham1, Simon Hatcher4, Allan House2,
Katie Martin3, Louise Pembroke2, David Protheroe3, Sandy Tubeuf2 and Amanda Farrin1Abstract
Background: Around 150,000 people each year attend hospitals in England due to self-harm, many of them more
than once. Over 5,000 people die by suicide each year in the UK, a quarter of them having attended hospital in the
previous year because of self-harm. Self-harm is a major identifiable risk factor for suicide. People receive variable
care at hospital; many are not assessed for their psychological needs and little psychological therapy is offered.
Despite its frequent occurrence, we have no clear research evidence about how to reduce the repetition of self-harm.
Some people who have self-harmed show less active ways of solving problems, and brief problem-solving therapies
are considered the most promising psychological treatments.
Methods/Design: This is a pragmatic, individually randomised, controlled, feasibility study comparing interpersonal
problem-solving therapy plus treatment-as-usual with treatment-as-usual alone, for adults attending a general hospital
following self-harm. A total of 60 participants will be randomised equally between the treatment arms, which will be
balanced with respect to the type of most recent self-harm event, number of previous self-harm events, gender and
age. Feasibility objectives are as follows: a) To establish and field test procedures for implementing the problem-solving
intervention; b) To determine the feasibility and best method of participant recruitment and follow up; c) To assess
therapeutic delivery; d) To assess the feasibility of obtaining the definitive trial’s primary and secondary outcomes; e) To
assess the perceived burden and acceptability of obtaining the trial’s self-reported outcome data; f) To inform the
sample size calculation for the definitive trial.
Discussion: The results of this feasibility study will be used to determine the appropriateness of proceeding to a
definitive trial and will allow us to design an achievable trial of interpersonal problem-solving therapy for adults
who self-harm.
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Self-harm is usually defined in UK health services as
intentional self-poisoning or self-injury, irrespective of
motivation [1]. It has been a major health problem in
the UK for 50 years. Rates have never been collected
for England nationally, but estimates based on the UK
Department of Health funded multicentre monitoring
project (in the cities of Manchester, Oxford and Derby)
suggest that current rates are a little below their highest
ever levels seen in 2003: rates in males are around 350
and in females 480 per 100,000 per annum [2]. Hospitals
in England deal with an estimated 220,000 episodes
undertaken by 150,000 people each year [3]. Around
80% of these hospital episodes are self-poisoning (usually
medicines overdose) while 15 to 20% are injuries (most
commonly self-cutting). People who self-harm are high
users of health and social care services [4] and two-thirds
are aged under 35 years [3]. Time-to-event curves based
on 11,000 consecutive self-harm episodes in Leeds between
October 2004 and September 2007 show evidence for a
difference in repetition rates of self-harm between age
groups. Those aged between 30 and 59 years are at the
highest risk of repetition whilst those aged over 60 are at a
reduced risk compared to other age groups (unpublished
data, D Owens, R Kelley, A House). Self-harm has a strong
link with suicide: 7 per 1000 people die by suicide in the
year after attending hospital with a non-fatal episode of
self-harm (60 times higher than the general population
risk); by 15 years after self-harm, as many as 30 per 1000
people will have died by suicide [1,5-7]. A quarter of
the 5000 to 6000 annual suicides in the UK are pre-
ceded by a hospital visit due to non-fatal self-harm in
the previous year [8]: it is a major identifiable risk fac-
tor for suicide. There is also an excess of premature
deaths in those with a history of self-harm from natural
causes and accidents [9-11], with many life years lost -
particularly among young people. Non-fatal repetition
is common (1-year repetition rates are 16% or more)
[5] and is associated with distress and unresolved
interpersonal problems [12].
UK hospital services for people who self-harm are in-
consistent; only around half of patients receive a basic
assessment of their state of mind and social circumstances
before discharge from emergency departments or medical
wards [13]. Unfortunately there is no consensus that
intervention at this stage is worthwhile and so therapy
is not routinely offered. Despite more than 40 randomised
controlled trials in self-harm, a Cochrane review [14]
found only small and methodologically poor trials had
been previously conducted and no clear evidence that
intervention reduces repetition. The review suggested
potential benefit from small trials involving problem-
solving therapy, a brief and focused psychological interven-
tion with a proven benefit in depression that is known toreduce hopelessness and suicidal ideation [15], concluding
that ‘larger trials are badly needed’. A comprehensive
American review [16] similarly judged the existing studies
to have three main limitations: lack of power, poor descrip-
tion of standard care and inconsistent age ranges across
studies. It further stated that the ‘trends suggested incre-
mental benefits from some interventions (in particular,
problem-solving therapy for people aged 15 or older)’. It is
therefore not surprising that the UK’s National Institute
for Health and Clinical Excellence (NICE) guideline on
self-harm reported that, as far as psychological interven-
tion is concerned, there was ‘insufficient evidence to make
any positive or negative recommendations’ [17], a view
echoed in a 2010 report from the UK Royal College of
Psychiatrists [18].
Trial evidence that post-dates these reviews adds little to
guide routine practice. One UK multicentre randomised
controlled trial (RCT) of ‘manual-assisted cognitive behav-
ioural therapy’ [19] failed to find any clear benefit from the
new treatment, or any indications of how to steer delivery
of interventions for self-harm in the UK National Health
Service (NHS). It was, however, underpowered for the
following reasons: it was restricted to a study sample
unrepresentative of the population of people attending
hospital because of self-harm; many of the participants
in the active treatment arm did not receive the interven-
tion; and the intervention itself was not, on theoretical
or empirical grounds, adequately designed for use in
self-harm. Two American trials showed benefits with
highly selected participants and intensive forms of expert
therapy: 1) ten sessions of cognitive therapy reduced non-
fatal repetition in people judged to have made suicide
attempts [20] and 2) intensive dialectical behaviour
therapy reduced repetition of self-harm in young women
with a diagnosis of borderline personality disorder [21].
Costs, in terms of time in therapy and therapist expertise,
preclude the widespread use of either of these interven-
tions for subgroups of patients in UK hospitals, and the
cost-effectiveness of such interventions for self-harm is
unknown. A New Zealand trial of problem-solving therapy
found that it was effective in preventing repeat presenta-
tion to hospital due to self-harm at one year in those who
repeat self-harm, but not in those whose index admission
was their first episode [22]. In its guidance on the lon-
ger term management of self harm, NICE continues to
emphasise the need for further research into the mo-
dality, duration, and extent of benefit for therapy inter-
ventions, carried out in ‘real-world’ clinical settings
[23]. A future definitive RCT is planned, however this
feasibility study is first required to inform the design of
such a large trial. The projected definitive trial will test
the hypothesis that brief problem-solving therapy, when
compared with treatment as usual, will reduce repetition
(whether fatal or non-fatal) of self-harm; the present
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pave the way for the successful undertaking of a definitive
trial.
Methods/Design
Aims and objectives
MIDSHIPS is a pragmatic, multi-centre, individually
randomised, controlled feasibility study, designed to de-
termine the practicability of undertaking a definitive RCT
of interpersonal problem-solving therapy plus treatment-
as-usual (PST + TAU), compared with treatment-as-usual
only (TAU), for adults who attend a general hospital due
to self-harm.
Objectives relate to the feasibility of implementing a
definitive RCT. The content of the manual and procedures
for training therapists in PST, recruiting and training ther-
apists, assessing therapist competence, and determining
procedures for therapist supervision must be established.
The evaluation of processes to screen patients for eligibility,
determining feasibility and best methods of recruitment,
and establishing participant uptake and retention during
follow up must also be examined. It is important to estab-
lish the retention rate in therapy, methods for measuring
adherence to PST, and characterising the range of TAU
offered and attended. It is also essential to assess the
feasibility of collecting the primary outcome for the
definitive trial (repeat attendance at hospital following
self-harm) from hospital records, establishing likelihood of
obtaining the main trial’s secondary outcomes (Short
Form 36, healthcare resource use, self-reported self-harm)
via postal administration or telephone interviews, and
assessing the burden and acceptability of self-reported
outcome data. Finally, the variability of outcomes must be
estimated in order to inform the sample size calculation
for a definitive trial.
Setting
A total of 60 participants (30 in each arm) will be
recruited following attendance at a general hospital as a
result of self-harm. The three hospitals involved are
those whose mental health services are provided by the
Leeds and York Partnership NHS Foundation Trust
(LYPFT). People not approached to take part in the
study can self-refer, provided that they have recently
attended the general hospital due to self-harm, through
the provision of information about the trial at the Leeds
Survivor Led Crisis Service.
Participants
Inclusion criteria
To be included in the study, participants must meet the
following eligibility criteria: a) be aged 18 years or over; b)
have attended the emergency department or been admit-
ted to a general hospital as a consequence of self-harm(intentional self-poisoning or self-injury irrespective of
motivation) within the last six weeks; c) not already be
participating in the MIDSHIPS trial; and d) where the
presenting episode is due to alcohol or recreational
drugs, the participant explicitly stated that they were
intending self-harm by use of alcohol or recreational
drugs.
Exclusion criteria
Participants will be ineligible for the study if they meet
any of the following criteria: a) they are involved in another
research project or clinical service involving a conflicting
intervention such as the Personality Disorder service; b)
they do not live in the LYPFT catchment area; c) they do
not provide fully informed written consent; d) they lack the
capacity to comply with trial requirements; e) they are not
sufficiently proficient in English to contribute to the data
collection required for the research; f) there is a perceived
risk of violence towards the therapist or researcher; and g)
the researcher is unable to contact the participant within
eight weeks following the self-harm event.
Recruitment
Patients attending hospital following self-harm receive a
mental health assessment by the clinical staff following
physical treatment, during which formal screening for
eligibility occurs. Eligible patients are given the MID-
SHIPS study card, which briefly describes the study, and
are asked to provide written permission for a researcher
to contact them. For those who self-refer to the study
via the Leeds Survivor Led Crisis Service, the clinical
staff review completed study cards, determine eligibility
and if appropriate, provide the researcher with the patient’s
details.
Following referral, the researcher telephones those
who have consented to be contacted to explain the study
in more detail and establish full eligibility. The MIDSHIPS
participant information sheet is sent to those eligible, who
then have at least 24 hours to read and digest the informa-
tion before the baseline visit, at which written informed
consent is obtained.
To inform generalisability of the study results, screen-
ing logs are completed for all people screened for entry
into MIDSHIPS; for those screened and not recruited,
anonymised data are collected on age, gender, reasons
for ineligibility and reasons for non-randomisation.
Randomisation
Consenting participants are randomised on a 1:1 basis to
receive PST + TAU or TAU alone via the Clinical Trials
Research Unit’s (CTRU) automated 24-hour randomisa-
tion system. A computer generated minimisation algo-
rithm incorporating a random element is used to ensure
the treatment arms are well balanced for the following
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leading to hospital attendance, prior to baseline assessment
(one, more than one), b) type of most recent episode (self-
poisoning, self-injury, both injury and poisoning combined),
c) gender (male, female) and d) age (<30, 30 to 59, ≥60).
Participants and therapists are, of necessity, aware of
treatment allocation, but the collection of outcome data
by researchers is undertaken blind to this knowledge.
Intervention
Treatment-as-usual
Treatment following self-harm varies and may involve re-
ferral to a multi-disciplinary mental health team, referral
to a mental health crisis team and recommendation for
attendance at other services including alcohol and drug
treatment centres. In many instances in UK current
clinical practice, no aftercare is offered, and the only
action to follow discharge from hospital is a letter sent
to the general practitioner summarising the episode.
TAU for randomised participants is recorded in both
arms of the study. In order to avoid contamination
across the two arms of the trial, we ensured that the
therapists did not participate in the TAU activity.
Interpersonal problem-solving therapy
Overwhelming problems can have an adverse effect on
people’s existing problem-solving skills, such that impul-
sive responding and incomplete solutions may become
more likely. In people who have self-harmed, the result
may be less active problem-solving, reliance on the actions
of others, waiting for resolution, and limited generation of
alternative solutions – all of which reinforce existing nega-
tive beliefs about self and self-blame. Interpersonal PST is
an established, brief, focused, and readily-learned psycho-
therapy with a proven benefit for depression and is known
to reduce hopelessness and suicidal ideation [15]. In a
New Zealand RCT of PST, seeking to reduce hopelessness
and repetition of self-harm [22], the research team suc-
cessfully amended the therapy to fit the needs of their
patients who had self-harmed. This manual, along with
training processes and client workbooks, has been adapted
for UK NHS use. Trial therapists have been recruited, as a
part-time secondment, from the clinical mental health
service in Leeds. The target groups of staff for this recruit-
ment were experienced but not senior practitioners in
mental health nursing, occupational therapy, or social
work. Training in problem-solving therapy has been de-
livered as a three-day course followed up with supervi-
sion sessions with a senior psychiatrist with experience
in self-harm management and problem-solving therapy
(A House).
Participants randomised to PST receive up to six one-
hour weekly individual sessions delivered one-to-one by
the trial therapists. Sessions focus on the identificationof current problems and a structured psycho-educative
approach to problem-solving. In addition, participants
are offered an optional ‘booster’ session, approximately
six to eight weeks following the end of therapy.
The therapists receive regular supervision in the use of
the problem-solving therapy as part of the research pro-
cedure, and participants in the trial remain patients of
the clinical service (the single UK National Health Ser-
vice Trust) from which they are recruited. The therapists
can urgently refer any clinical emergencies or concerns
about the participant’s mental state to the standard clinical
service, to be dealt with promptly through the existing
arrangements for urgent assessment and care.Data collection
At baseline, the researcher collects details of the index
self-harm event (the event leading to hospital attendance
which prompted entry into the study), self-harm history,
current physical and mental health, social and medical
history, current psychotropic medications, education,
and employment details. At baseline and at three and six
months post-randomisation, the participant is asked to
complete the Short-Form 36 [24] and a trial-specific
questionnaire about the use of health and social care
resources, private expenses, and lost productivity. Self-
reported self-harm events are also collected at both
follow up time points. All follow up outcome data are
collected by post or by telephone following non-response
to postal reminders. Participants are sent £10 shopping
vouchers with each questionnaire mailing to thank them
for their time. On receipt of the six-month questionnaires
the researcher telephones the participant to assess the per-
ceived burden and acceptability of the task of completing
the research questionnaires, and obtains additional infor-
mation on treatment received and current psychotropic
medications via a trial-specific, semi-structured interview
schedule. A further £10 shopping voucher is sent follow-
ing this interview.
Data relating to therapy are collected directly from
therapists and case notes by UK Research Network staff
with support from CTRU. These data relate to therapy
(type, dates, number of sessions offered and attended and
contact between sessions), therapist supervision, referrals
to and attendance at other services (including the mental
health crisis team and alcohol and drug treatment centres),
and psychotropic medication details. Admissions to or at-
tendance at hospital and all-cause mortality are collected
from hospital records by the researcher.Outcomes
To establish the problem-solving intervention this requires
a finalised training manual and successfully imple-
mented procedures for recruiting and training therapists,
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assessing therapist competence and recording supervision.
Outcomes relating to recruitment methods, uptake
and follow up include screening, eligibility, consent, and
randomisation rates together with reasons for non-
participation and participant retention during follow-up.
To determine whether therapeutic delivery is successful
we will examine attendance, therapy completion rates,
and reasons for early dropout together with adherence to
therapy by participant and therapist. The range of TAU
pathways across treatment arms will also be investigated.
Outcomes related to follow up data collection will
include the proportion of participants with self-harm
repetition data - whether non-fatal or fatal (suicide), a
comparison of self-reported self-harm with data collected
from hospital records , the proportion of participants with
self-reported outcome data and an assessment of missing
data.
Statistical outcomes which will inform the sample size
calculation for a definitive trial include the repetition of
and time to self-harm leading to hospital attendance
within six months post-randomisation, and the difference
between arms, the variability of self-reported outcomes at
follow up and the difference in self-reported outcomes at
follow up.
A qualitative summary of burden and acceptability of
self-reported outcomes will also be achieved by examining
the participant follow-up interviews.
Sample size
As this is a feasibility study and effectiveness is not being
evaluated, formal power calculations are not appropriate.
It is recommended that feasibility studies recruit a mini-
mum of 30 participants per arm to allow for the investiga-
tion of parameters and outcomes for a definitive RCT
[25]. We therefore plan to recruit 60 participants in total,
randomised equally between TAU and PST +TAU.
Statistical analysis
Analysis will take place when the last participant has
completed follow up and all available outcome data are
received. Analyses will be descriptive in nature and will
provide estimates of key parameters for the definitive
RCT. No formal statistical testing will take place as the
focus will be on confidence interval estimation. All
analyses will be conducted on the intention-to-treat
population, with participants analysed according to rando-
mised arm, regardless of non-compliance with the proto-
col or withdrawal from the study.
The feasibility and success of the recruitment strategy
will be evaluated by summarising screening, eligibility,
consent and randomisation rates, both overall and by
centre. Reasons for dropout at each stage will also be
examined.To assess therapeutic delivery, participant attendance
will be summarised and will include the number of
participants successfully completing the required amount
of therapy as determined by the study therapist, the num-
bers of participants not attending any sessions and the
number of and reasons for, early dropouts from therapy.
Therapist adherence to the PST manual will be examined
by summarising therapy session content via therapist re-
ports and by an independent review of participant notes.
TAU data will be examined to enable us to map out the
TAU pathway of participants for the definitive trial.
Interview data from the PST therapists will be analysed
qualitatively and used to refine training and supervision
processes.
To inform the sample size calculation for the definitive
trial, repetition of and time to self-harm leading to hospital
attendance will be summarised by arm at six months
post-randomisation. Differences between arms and 95%
confidence intervals will be presented. In addition, the
proportion of participants with available self-harm data
accessed via hospital records will be compared to the
proportion of participants with self-reported self-harm.
Self-reported outcome data completion will be assessed
by summarising response rates at baseline and follow up.
The level of missing data (at the individual item level and
for entire outcome measures) together with qualitative
participant interview data will inform the appropriateness
of the tools and the level of burden for the definitive trial.
An exploratory cost-effectiveness analysis (using SF36 and
the health and social care resource use questionnaire)
will be produced, together with indicative costs for the
interventions.
Trial governance
Ethical approval was granted for this study by the Leeds
West Research Ethics Committee (Reference: 12/YH/022).
Research governance approval was gained via the National
Institute for Health Research Coordinated System for
gaining NHS Permissions (CSP 88012). NHS Permission
was granted by LYPFT (2011/302/E/L).
The Trial Management Group (TMG), comprising the
Chief Investigator, CTRU Team and Co-Investigators, are
responsible for the clinical setup, ongoing management,
promotion of the study, and interpretation of the results.
An independent Trial Steering Committee (TSC) pro-
vides independent and scientific oversight of the study
and comprises an independent Chair and five other
independent members (including two lay members). A
separate Data Monitoring and Ethics Committee is not re-
quired for a feasibility study of this nature, rather a sub-
committee of the TSC is convened as necessary to review
safety issues. The Sponsor (Leeds and York Partnership
NHS Foundation Trust) and the CTRU are responsible
for ensuring that the study is conducted in accordance
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Framework.
Discussion
At present, therapy is not routinely offered to people
attending hospital due to self-harm as there is no form
of therapy that has been proven to be effective [14,16].
The absence of effective treatment is one of the main
reasons why fewer than half of the people who come to
hospitals in the UK as a consequence of self-harm receive
an adequate psychosocial assessment of their needs [13].
Current evidence points towards effectiveness of brief
problem-solving therapy but, if it is to become a routinely
available treatment in the NHS, we will need clear evidence
from a large, multicentre, pragmatic trial in the UK and an
economic evaluation; this feasibility study paves the way to-
wards badly needed improvement in patient experience
and outcome after self-harm.
The feasibility study has limitations and is by necessity
a small undertaking when compared with the definitive
trial. For example, Leeds and York mental health services
provide for a large urban area (Leeds, England’s fifth
largest city), a smaller urban area (York), and a very large
rural region in North Yorkshire. The present feasibility
study, set up as it is in just one locality (although one rea-
sonably typical of England), will vary from some of the
centres that will need to be recruited in a main trial. The
main trial will also have more therapists than involved in
the present study. We expect that the present study will
provide, at reasonable financial and ethical cost, valuable
information needed for the planning of the most important
aspects of a definitive trial – concerning the therapy man-
ual, recruitment and training of therapists, recruitment and
retention of participants, delivery of therapy, adherence
to the therapy manual, and the collection of baseline
and follow up data.
Trial status
Recruitment of participants is ongoing in two study centres
within LYPFT.
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